Search

Displaying all 7 results
  1. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant g...

    Products: Sutent, SUTENT
  2. Indication

    Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin

    go.drugbank.com/conditions/DBCOND0146859
    Drugs: Sunitinib
  3. Indication

    Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin

    go.drugbank.com/conditions/DBCOND0146858
    Drugs: Sunitinib
  4. Indication

    Adenocarcinoma, Renal

    go.drugbank.com/conditions/DBCOND0126095
    Drugs: Belzutifan · Interferon alfa · Pembrolizumab · Sunitinib · Tivozanib
  5. Indication

    Gastrointestinal Stromal Tumor (GIST)

    go.drugbank.com/conditions/DBCOND0037254
    Drugs: Imatinib · Sorafenib · Sunitinib
  6. Indication

    Renal Cell Carcinoma Recurrent

    go.drugbank.com/conditions/DBCOND0078870
    Drugs: Sunitinib
  7. Pathway

    Sunitinib Action Pathway

    smpdb.ca/view/SMP0126868
    Drug action

    Sunitinib is a chemotherapeutic agent and receptor tyrosine kinase inhibitor utilized in the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Approved by the US FDA on January 26, 2006...

    Drugs: Sunitinib · Calcium